{
    "nct_id": "NCT00788047",
    "title": "A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon [PF-01913539] On The Single-Dose Pharmacokinetics Of The CYP2D6 Substrate Dextromethorphan In Healthy Subjects",
    "status": "COMPLETED",
    "last_update_time": "2009-03-05",
    "description_brief": "This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose administration to healthy adult subjects.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "BASIC_SCIENCE",
    "results": null,
    "target_category": "Cognitive enhancer",
    "drug": [
        "Dimebon (latrepirdine; PF-01913539)",
        "Dextromethorphan (CYP2D6 probe substrate, co-administered in this PK study)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The investigational agent is Dimebon (latrepirdine, PF-01913539), a small-molecule repurposed antihistamine evaluated for symptomatic benefit in Alzheimer's disease (aiming to improve cognition) rather than as a biologic. Evidence of Dimebon's small-molecule, multi-receptor and mitochondrial activity and its clinical testing for cognitive outcomes is documented. \ue200cite\ue202turn0search7\ue202turn0search6\ue201.",
        "Act (trial details): The described study is a Phase 1 drug\u2013drug interaction / pharmacokinetic study of Dimebon's effect on the CYP2D6 probe dextromethorphan (NCT00788047), i.e., a PK interaction study in healthy subjects rather than a diagnostic or non-therapeutic procedure. The trial record and listing identify Dimebon (PF-01913539) as the investigational drug. \ue200cite\ue202turn0search0\ue202turn0search2\ue201.",
        "Act (mechanism/context): Preclinical and clinical literature describe multiple possible actions (mitochondrial effects, receptor affinities, anticholinesterase and NMDA-related effects) and Dimebon was tested for cognitive benefit in AD (Phase II showed cognitive signals; Phase III CONNECTION later failed to confirm benefit). While some preclinical work reported effects on amyloid/tau in models, the compound is a small molecule with unclear direct anti-amyloid/tau targeting in humans. \ue200cite\ue202turn0search5\ue202turn0search8\ue202turn0search7\ue201.",
        "Reflect (classification choice): Given that Dimebon is a small molecule tested primarily for symptomatic cognitive improvement in AD (rather than a biologic or a canonical pathology-targeting small molecule like an anti-amyloid or anti-tau drug), the best fit among the provided categories is 'Cognitive enhancer'. There is some ambiguity because preclinical studies suggested mitochondrial/neuroprotective effects (potential disease-modifying hypothesis), but the clinical program and the described PK study context support a symptomatic/cognitive-enhancement interpretation. \ue200cite\ue202turn0search6\ue202turn0search5\ue201."
    ],
    "agent_type": "M) Synaptic Plasticity/Neuroprotection",
    "explanation_agent": [
        "Reason: Dimebon (latrepirdine) is an orally active small molecule repurposed from an antihistamine that was developed and tested clinically as a symptomatic cognitive enhancer with reported effects on multiple neurotransmitter receptors (e.g., AMPA/NMDA, serotonergic subtypes) and with reported mitochondrial / neuroprotective and autophagy\u2011related activity. These properties align best with a CADRO category emphasizing synaptic function and neuroprotection rather than amyloid/tau or a purely metabolic-only classification. \ue200cite\ue202turn0search3\ue202turn0search2\ue202turn0search4\ue201",
        "Act: Trial details show this specific study (NCT00788047) is a Phase 1 pharmacokinetic / drug\u2013drug interaction study of steady\u2011state dimebon on the CYP2D6 probe dextromethorphan \u2014 i.e., a PK study in healthy volunteers rather than an amyloid- or tau\u2011targeting intervention. The investigational drug is latrepirdine/dimebon and the clinical program aimed at symptomatic cognitive benefit. Given the drug\u2019s multi\u2011receptor and neuroprotective claims and the symptomatic cognitive focus, the most specific CADRO fit is M) Synaptic Plasticity/Neuroprotection. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Reflect: There is ambiguity because preclinical studies also report mitochondrial stabilization, improved bioenergetics, and induction of autophagy \u2014 features that could map to J) Metabolism and Bioenergetics or I) Proteostasis \u2014 and because the compound has heterogeneous receptor activity. However, the clinical rationale and primary symptomatic/cognitive intent (and reported effects on neurotransmission and neuroprotection) point to M) Synaptic Plasticity/Neuroprotection as the best single CADRO category. If you prefer a classification that emphasizes the multiple disparate mechanisms, R) Multi\u2011target would also be defensible. Key supporting sources: NCT trial record (PK study), preclinical mitochondrial data, autophagy/A\u03b2 findings, and reviews of the latrepirdine clinical program. \ue200cite\ue202turn0search0\ue202turn0search3\ue202turn0search2\ue202turn0search4\ue201",
        "Selected web search results supporting the classification: 1) NCT00788047 Phase 1 PK study record (dimebon + dextromethorphan). \ue200cite\ue202turn0search0\ue201 2) PubMed: dimebon enhances mitochondrial function / protects neurons (mechanistic preclinical data). \ue200cite\ue202turn0search3\ue201 3) PubMed: latrepirdine enhances autophagy and reduces intracellular A\u03b2 in model systems. \ue200cite\ue202turn0search2\ue201 4) Review/summary of latrepirdine clinical trials and mechanisms (CONNECTION/CONCERT context). \ue200cite\ue202turn0search4\ue201"
    ]
}